13 completed, 6 terminated, 4 withdrawn, 1 recruiting. 24 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 13, Terminated 6, Withdrawn 4, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Insulinoma: new trials by email Literature Review of Insulinoma trials Research Report on Insulinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism 18F-Fluoro Dopa PET/MRI Imaging - Hyperinsulinism | Phase 2 | Recruiting | Washington University School of Medicine | 100 | 2020-09-10 | 2025-12-19 |
| Pasireotide in Hyperinsulinemic Hypoglycemia Pasireotide 0.6Mg Solution for Injection, Saline Solution - Congenital Hyperinsulinism, Insulinoma | Phase 2 | Withdrawn | Montefiore Medical Center | 2017-04-01 | 2021-05-14 | |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH 68Ga-NODAGA-exendin 4 PET/CT - Insulinoma | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 56 | 2015-04-01 | 2021-06-16 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Terminated | Emory University | 2 | 2014-11-01 | 2017-02-03 |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery everolimus, placebo - Gastrinoma, Glucagonoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 2 | 2014-04-10 | 2023-06-29 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors temozolomide, capecitabine - Gastrinoma, Glucagonoma | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 144 | 2013-08-08 | 2026-09-29 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
| Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Bortezomib, Panobinostat - Pancreatic Cancer | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 7 | 2010-09-01 | 2017-12-28 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-03-01 | 2020-04-03 |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors capecitabine, cisplatin, streptozocin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 84 | 2005-08-01 | 2013-08-07 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors bevacizumab, 5-fluorouracil, leucovorin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 36 | 2005-06-08 | 2023-05-22 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors sorafenib tosylate - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2005-06-01 | 2014-11-17 |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer isolated perfusion, melphalan - Cancer | Phase 2 | Completed | Delcath Systems Inc. | 56 | 2004-09-01 | 2013-10-23 |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery fluorouracil, irinotecan hydrochloride, leucovorin calcium - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 20 | 2004-05-01 | 2016-05-30 |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors romidepsin, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2004-03-01 | 2013-06-04 |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors gefitinib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 90 | 2003-12-01 | 2013-06-04 |
Showing 20 of 24. Sign in to see all of them.
Glucagonoma (20) · Somatostatinoma (20) · Gastrinoma (18) · Carcinoma, Islet Cell (17) · Vipoma (10) · Adenoma, Islet Cell (8) · Neoplasms (6) · Neuroendocrine Tumors (4) · Pancreatic Neoplasms (3) · Carcinoma, Medullary (2) · Hyperinsulinism (2) · Lung Neoplasms (2) · Pheochromocytoma (2) · Adenocarcinoma Of Esophagus (1)
Adenoma (24) · Digestive System Diseases (24) · Digestive System Neoplasms (24) · Endocrine Gland Neoplasms (24) · Endocrine System Diseases (24) · Neoplasms by Histologic Type (24) · Neoplasms by Site (24) · Neoplasms, Glandular and Epithelial (24) · Pancreatic Diseases (24) · Adenocarcinoma (21) · Carcinoma (21) · Carcinoma, Neuroendocrine (21) · Neoplasms, Germ Cell and Embryonal (21) · Neuroectodermal Tumors (21) · Pancreatic Neoplasms (21)
Capecitabine (3) · Octreotide (3) · Bevacizumab (2) · Bortezomib (2) · Everolimus (2) · Fluorouracil (2) · Leucovorin (2) · Temozolomide (2) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Biological Therapy (1) · Cisplatin (1) · Gefitinib (1) · Injections (1) · Irinotecan (1)
National Cancer Institute (NCI) (4) · ECOG-ACRIN Cancer Research Group (2) · Eastern Cooperative Oncology Group (2) · Academic and Community Cancer Research United (1) · British Columbia Cancer Agency (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Delcath Systems Inc. (1) · Emory University (1) · Federation Francophone de Cancerologie Digestive (1) · Masonic Cancer Center, University of Minnesota (1) · Memorial Sloan Kettering Cancer Center (1) · Montefiore Medical Center (1) · Ohio State University Comprehensive Cancer Center (1) · Radboud University Medical Center (1) · Shaheen Shagufta (1)
United States (17) · Canada (1) · United Kingdom (1)
Mary Mulcahy, MD (2) · Timothy Hobday (2) · Ana Maria Arbelaez, MD, MSCI (1) · Arkadiusz Dudek, MD (1) · Emily Bergsland (1) · Emily K. Bergsland, MD (1) · Erika Brutsaert, M.D., M.P.H. (1) · Francois Benard, MD (1) · Guillaume Cadiot (1) · James Yao (1) · Kyle Holen, MD (1) · Leonard B. Saltz, MD (1) · Manisha H. Shah, MD (1) · Manisha Shah (1) · Martin Gotthardt, Prof. Dr. (1)
PMID 21831734, PMID 25956795, PMID 29853660, PMID 36260828, PMID 39863139
N01CM62205 (2), U10CA021115 (2), 2014 (1), N01CM62202 (1), P30CA014089 (1), P30CA016672 (1), U01CA062490 (1), U01CA076576 (1), U10CA023318 (1), U10CA180820 (1)